Business
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate\n \n \nMarina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate\n\nPatents Covering the Company's SMARTICLES(R), tkRNAi, DILA2 and Lipopeptide Delivery Technologies Are Granted in Europe, Japan, Australia and China, Respectively\n\n \n BOSTON, MA--(Marketwired - Sep 11, 2014) - Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES® in Europe; TransKingdom RNA™ interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications. \n \"Marina Biotech continues to extend patent coverage for its nucleic acid delivery technologies in key commercial markets,\" stated J. Michael French, president & CEO of Marina Biotech. \"Looking broadly at our nucleic acid delivery capability, we believe we are the only company that has a delivery technology, SMARTICLES, in clinical development that is: (1) delivering both a single-stranded and double-stranded nucleic acid; (2) delivering to both the cell nucleus (ProNAi Therapeutics' single-stranded DNA decoy) and cell cytoplasm (Mirna Therapeutics' double-stranded microRNA mimic); and (3) delivering a lipid nanoparticle outside the liver, (i.e. tumors). Further, we believe we are the only company that has two separate and distinct delivery technologies, SMARTICLES (lipid nanoparticle) and tkRNAi (engineered bacteria), in clinical development. Finally, we are the only company with an orally administered RNAi-based therapeutic in clinical development - the Company's CEQ508 for the treatment of Familial Adenomatous Polyposis. Taken in its entirety, we believe our delivery platform is unparalleled within the sector and unequalled in c...